Trial Profile
A Phase 1, Open-label, 2-panel, Randomized, Crossover Study in Healthy Adult Subjects to Assess the Relative Oral Bioavailability of a Single 600-mg Dose of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation, Under Fed and Fasted Conditions
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pimodivir (Primary)
- Indications Influenza A virus infections
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 04 Jul 2016 Status changed from recruiting to completed.
- 04 Feb 2016 New trial record